Oral GLP-1 Drug Foundayo Improves Diabetes Control

The oral GLP-1 drug orforglipron, marketed as Foundayo, has demonstrated significant improvements in glycemic control and body weight reduction for patients with type 2 diabetes. Results from the ACHIEVE-5 trial, presented at the American Diabetes Association annual meeting, showed that adding Foundayo to basal insulin therapy led to substantial benefits for participants. This development marks a potential simplification in diabetes management by offering an oral alternative to injectable GLP-1 receptor agonists.

The ACHIEVE-5 trial specifically evaluated the efficacy and safety of orforglipron in individuals with type 2 diabetes who were already on basal insulin. The study found that the addition of the oral medication resulted in a notable decrease in HbA1c levels, a key indicator of long-term blood sugar control. Furthermore, participants treated with Foundayo experienced a significant reduction in body weight, a common comorbidity and treatment goal in type 2 diabetes management.

This oral formulation offers a more convenient treatment option compared to existing injectable GLP-1 medications. The availability of an oral pill could enhance patient adherence and potentially broaden access to this class of drugs, which are known for their dual benefits of glycemic control and weight loss. The findings suggest that orforglipron could become a valuable tool in the therapeutic arsenal for managing type 2 diabetes, offering a less burdensome regimen for many patients.